Johnson & Johnson third-quarter 2026 earnings and operational results
Johnson & Johnson reported $25.4 billion in worldwide revenue for the third quarter, released on October 21, 2026. Net income was $210 million. Diluted earnings per share (EPS) fell to $0.09 from $2.12 a year earlier.
Key points
- Revenue grew 5.9% year-over-year to $25.4 billion for the period ended September 27, 2026.
- Innovative Medicine segment sales rose 7.7% to $16.8 billion in the third quarter.
- Biosimilar competition is expected to continue putting downward pressure on STELARA operational sales growth.
Third-quarter financial results
Revenue grew 5.9% year-over-year to $25.4 billion for the period ended September 27, 2026. Net income was $210 million. Third-quarter EPS declined 95.8%.
Quarter vs the same quarter a year earlier
Operational activity and policy changes
Innovative Medicine segment sales rose 7.7% to $16.8 billion in the third quarter. Biosimilar competition for STELARA negatively impacted the segment’s operational sales growth by approximately 6.9%.
The company also revised its 340B pricing policy. Covered entities must now submit claims data to receive discounts, and the choice of contract pharmacies is limited to one per facility.
Risks
Biosimilar competition is expected to continue putting downward pressure on STELARA operational sales growth.
What to watch
Shareholders should monitor the impact of biosimilar competition on Innovative Medicine sales in future reports. It is also important to observe whether the updated 340B policy affects product sales figures.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Johnson & Johnson
A notification in your browser or on your phone when we publish about Johnson & Johnson. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
